Role of Endogenous TGF-β Family in Myogenic Differentiation of C2C12 cells

Yuuma Furutani¹, Takenao Umemoto¹, Masaru Murakami², Tohru Matsui¹ and Masayuki Funaba¹*

¹Division of Applied Biosciences, Kyoto University Graduate School of Agriculture, Kyoto 606-8502, Japan
²Laboratory of Molecular Biology, Azabu University School of Veterinary Medicine, Sagamihara 229-8501, Japan

Running title: ENDOGENOUS TGF-β FAMILY IN MYOGENIC CELLS

*Corresponding author: Masayuki Funaba, Ph.D.
Division of Applied Biosciences
Kyoto University Graduate School of Agriculture
Kitashirakawa Oiwakecho, Kyoto 606-8502, Japan
Tel.: +81-75-753-6055
Fax: +81-75-753-6344
E-mail: mfunaba@kais.kyoto-u.ac.jp
ABSTRACT
The present study evaluated endogenous activities and the role of BMP and TGF-β, representative members of the TGF-β family, during myotube differentiation in C2C12 cells. Smad phosphorylation at the C-terminal serines was monitored, since TGF-β family members signal via the phosphorylation of Smads in a ligand-dependent manner. Expression of phosphorylated Smad1/5/8, which is an indicator of BMP activity, was higher before differentiation, and rapidly decreased after differentiation stimulation. Differentiation-related changes were consistent with those in the expression of Ids, well-known BMP-responsive genes. Treatment with inhibitors of BMP type I receptors or noggin in C2C12 myoblasts down-regulated the expression of myogenic regulatory factors, such as Myf5 and MyoD, leading to impaired myotube formation. Addition of BMP-2 during the myoblast phase also inhibited myotube differentiation through the down-regulation of Myf5 and MyoD. In contrast to endogenous BMP activity, the phosphorylation of Smad2, a TGF-β-responsive Smad, was higher 8 to 16 days after differentiation stimulation. A-83-01, an inhibitor of TGF-β type I receptor, increased the expression of Myf5 and MyoD, and enhanced myotube formation. The present results reveal that endogenous activities of the TGF-β family are changed during myogenesis in a pathway-specific manner, and that the activities are required for myogenesis.

KEY WORDS: TGF-β family; BMP; TGF-β; myotube differentiation
INTRODUCTION

Skeletal muscle formation consists of a complex set of differentiation steps: commitment of mesenchymal stem cells to myoblast lineage cells, progression of differentiation with the expression of muscle-cell-specific proteins, and fusion of myoblasts into multinucleated myotubes. Skeletal myogenic differentiation is principally governed by activities of the MyoD family that are basic helix-loop-helix (bHLH) transcription factors. The MyoD family is also known as myogenic regulatory factors (MRFs), i.e., MyoD, Myf5, myogenin and MRF4. MRFs form a complex with E proteins, another class of bHLH transcription factors, such as E12 and E47, and stimulate the transcription of skeletal muscle-specific genes through binding to E-box (CANNTG) in the regulatory region [Ludolph and Konieczny, 1995; Perry and Rudnicki, 2000; Lluis et al., 2006]. To accomplish appropriate myogenesis, activities of MRFs must be strictly regulated.

Transforming growth factor-β (TGF-β) family members, i.e., TGF-βs, activins and bone morphogenetic proteins (BMPs), are pluripotent growth factors involved in diverse physiological processes, and also participate in myogenesis in a ligand-dependent manner [Derynck et al., 2008]. Exogenous administration of TGF-β and myostatin to the culture medium inhibited myogenesis through the down-regulation of MRF expression [Vaidya et al., 1989; Brennan et al., 1991; Langley et al., 2002]. Exogenous administration of BMPs also inhibited myogenic differentiation, but in a different fashion from TGF-β-induced inhibition of myogenesis; BMP-2 treatment induced the transdifferentiation of myoblasts to osteoblast lineage cells [Katagiri et al., 1994; Lee et al., 2000; Maeda et al., 2004]. These studies, however, examined the effects of ligand administered exogenously, and there is little information on the role of the endogenous TGF-β family during myogenesis.
Members of the TGF-β family elicit their activities through a complex formation consisting of ligand, type I and type II receptor serine/threonine kinases. Activation of the type I receptor through transphosphorylation by the type II receptor induces the phosphorylation of C-terminal serines of receptor-regulated (R)-Smad. R-Smad is categorized into two subclasses: BMP pathway-specific R-Smad (Smad1, 5 and 8), and activin/TGF-β pathway-specific R-Smad (Smad2 and 3) [Feng and Derynck, 2005; Massagué et al., 2005; Heldin, 2008]. Subsequently, phosphorylated R-Smad forms complexes with common Smad, Smad4, which accumulate in the nucleus where they participate in transcriptional regulation of target genes. Thus, serine phosphorylation of R-Smad at the C-terminus is a key event in TGF-β family signaling [Feng and Derynck, 2005; Massagué et al., 2005; Heldin, 2008]. The objective of this study is to clarify the activities and roles of endogenous TGF-β family, especially BMPs and TGF-βs during myogenesis; the activities of the TGF-β family were monitored by the expression of phosphorylated R-Smad in a C2C12 myotube differentiation model.

MATERIALS AND METHODS

MATERIALS

The following reagents were purchased: recombinant BMP-2 and recombinant noggin were from R&D Systems (Minneapolis, MN); dorsomorphin and A-83-01 were from Calbiochem; LDN-193189 was from Stemgent (San Diego, CA); rabbit polyclonal antibody against phospho-Smad1 (Ser463/Ser465) / Smad5 (Ser463/Ser465)/ Smad8 (Ser426/Ser428) (#9511) and phospho-Smad2 (Ser465/Ser467) (#3101) were from Cell Signaling Technology; rabbit monoclonal antibody against Smad1 (ab33902), rabbit polyclonal antibody against Smad2 (ab63576), goat polyclonal antibody against Smad8 (ab48011), mouse monoclonal antibody against MyoD (ab16148) and β-actin (AC-15) were from Abcam; rabbit polyclonal antibody against Myf5 (C-20) was from Santa
Cruz Biotechnology; mouse monoclonal antibody against myosin heavy chain (MyHC) (MY-32) was from Sigma; Alexa Fluoro 488 was from Invitrogen.

CELL CULTURE
C2C12 myoblasts were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in growth medium, i.e., Dulbecco’s modified Eagle’s medium (DMEM) with heat-inactivated 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin, at 37°C under a humidified 5% CO₂ atmosphere. To induce differentiation from myoblasts to myotubes, the medium was replaced at confluence (day 0) with differentiation medium consisting of DMEM with 2% horse serum supplemented the antibiotics. To examine the effect of dorsomorphin and LDN-193189, BMP-specific inhibitors [Yu et al., 2008a, b], dorsomorphin at 4 µM, LDN-193189 at 100 nM or an equivalent amount of vehicle (DMSO: 0.04%) was added to growth medium from day -2 to day 0. To evaluate the effect of endogenous BMP activity, noggin, a BMP antagonist [Yanagita, 2005], was also added at 2.5 or 25 ng/ml from day -2 to day 0. To examine the effect of A-83-01, an activin/TGF-β-specific inhibitor [Tojo et al., 2005], A-83-01 at 4 µM or the indicated concentrations, or an equal amount of vehicle (DMSO: 0.08%) was added to differentiation medium from day 8 to day 12 or the indicated period.

WESTERN BLOTTING
To examine time-course changes in Smad expression, cells were recovered in 200 mM phosphate buffer, pH 7.4, 2 M NaCl, 2 mM Na₃VO₄, 1 mM PMSF and 1% aprotinin, and lysed by ultrasonication. Protein concentrations were measured by the Lowry method, and an equal amount of protein was subjected to Western blot analyses as described previously [Funaba and Murakami, 2008; Suenaga et al., 2010]. After incubation of the membranes with ECL Plus reagent (GE Healthcare), the
chemiluminescent signals were captured and quantified by a LAS4000 mini biomolecular imager (Fuji Film, Tokyo, Japan). To examine the effects of the inhibitor or BMP-2, cells were lysed in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 with phosphatase and protease inhibitors.

RT-PCR and qRT-PCR
RNA isolation, RT-PCR and qRT-PCR were carried out as previously described [Furutani et al., 2009; Suenaga et al., 2010]. The following oligonucleotides were used as PCR primers: 5’-tgaaaacaccagccacata-3’ and 5’-tgagccattccgacatac-3’ for Smad1 (Genbank accession number: NM_008539), 5’-gcacgttagaagactaagaag-3’ and 5’-cactactaggcactcagca-3’ for Smad2 (NM_010754.4), 5’-ccagcacacataacttgg-3’ and 5’-cgctggtcagctcgtgta-3’ for Smad3 (NM_016769.4), 5’-gcctaagcagctcactgacc-3’ and 5’-gcagccagctgaatctct-3’ for Smad5 (NM_008541.2), 5’-cggatgttgtagtgaaggg-3’ and 5’-ggctggtcagctcgtct-3’ for Smad8 (NM_019483), 5’-tggtcagcctctgtaa-3’ and 5’-cctgtctcttaaaaaggagtta-3’ for Myostatin (NM_010834.2), 5’-gcacgacaggcata-3’ and 5’-cctcagctgctgatctct-3’ for Gremlin1 (NM_011824.3), and 5’-agcactcttggcagct-3’ and 5’-ggccgtgtaatccatcat-3’ for MyoD (NM_010866.2). PCR primers of inhibitor of DNA binding (I)ds, TGF-β2, TGF-β3, Myf5, myosin heavy chain IIb (MyHC IIb), Hprt1, and Gapdh were previously described [Furutani et al., 2009; Murakami et al., 2009]. The relative mRNA level was expressed as a ratio with the Hprt1 mRNA level.

IMMUNOFLUORESCENCE STAINING
Cells cultured on glass coverslips were washed with phosphate-buffered saline (PBS), and fixed with 4% paraformaldehyde in PBS. The fixed cells were treated with 0.1% Triton X-100 in PBS for permeabilization, followed by blocking with Ez Block (Atto, Tokyo, Japan) in TBS-T (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for
30 min. Cells were subsequently reacted with the primary antibody against MyHC in TBS-T for 1 h at 37°C. After washing with TBS-T, cells were incubated with Alexa Fluoro 488 and 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI) in TBS-T for 1 h. The number of nuclei was calculated by Image J (http://rsbweb.nih.gov/ij/). Fusion index was calculated as a ratio of the number of nuclei incorporated in myotubes to the number of total nuclei [Joulia et al., 2003].

RESULTS

BMP ACTIVITY IS HIGHER BEFORE DIFFERENTIATION, WHEREAS TGF-β ACTIVITY IS HIGHER AFTER DIFFERENTIATION IN C2C12 CELLS

To examine changes in endogenous BMP and activin/TGF-β activities during the differentiation of committed myoblasts, we first examined the phosphorylation of Smad1/5/8 and Smad2, respectively, by Western blot analyses using an antibody that recognizes the phosphorylation of C-terminal serines (Fig. 1A). When anti-phospho-Smad1/5/8 antibody was used, two bands were detected. Since the calculated molecular weight of Smad8 (48,420) is smaller than that of Smad1 (52,157) and Smad5 (52,172), the lower band may indicate phosphorylated Smad8. In fact, the lower band corresponded to the band detected by anti-Smad8 antibody (data not shown). The intensity of the lower band, i.e., phosphorylated Smad8, was higher before differentiation (Fig. 1A, lanes 1 and 2), and rapidly decreased after differentiation stimulation (Fig. 1A, lanes 3–7, Fig. 1B). By contrast, upper band intensity was relatively constant throughout the study. Since total Smad8 expression was also higher before differentiation (Fig. 1A, B), the ratio of phosphorylated Smad8 to total Smad8 was relatively constant throughout the study (Fig. 1B).

Western blot using anti-phosphorylated Smad2 antibody showed that a clear band was
detected on day 8 to 16 (Fig. 1A, lanes 5–7, Fig. 1C). The levels of total Smad2 were relatively lower but constant during myogenesis (Fig. 1A, C). Thus, the ratio of phosphorylated Smad2 to total Smad2 was higher on day 8 to 16 (Fig. 1C).

Gene transcript levels of Smad1 and Smad5 were constant throughout the study; the expression levels varied within 40% of the level on day -2 (Fig. 1D and E). By contrast, the level of Smad8 mRNA was decreased after differentiation stimulation to 16% of the basal level on day -2 (Fig. 1F), which was consistent with that of Smad8 protein (Fig. 1A). Variations of Smad2 and Smad3 expression were smaller during myogenesis, except for Smad3 expression on day 2 (Fig. 1G and H).

Ids, proteins with an HLH domain lacking the basic domain [Norton, 2000], are transcriptionally activated in response to BMP-induced Smad activation [Korchynskyi and ten Dijke, 2002; Miyazono et al., 2005; Murakami et al., 2009]. Similar to changes in the phosphorylated Smad1/5/8 level, gene transcript levels of Id1, Id2 and Id3 during myogenesis were higher on day -2 to 0, and rapidly decreased in response to differentiation stimulation (Fig. 2). Taking these results with the phosphorylated Smad levels together, it is suggested that endogenous BMP activity is higher in undifferentiated C2C12 cells.

To explore the possible molecules to induce endogenous BMP activity, we searched expression of BMPs and GDF family members, which induce Smad 1/5/8 phosphorylation and activation, in a cDNA microarray database (http://www.ncbi.nlm.nih.gov/geo/) thoroughly. No BMPs and GDFs exhibited higher expression before differentiation stimulation (data not shown). BMP activity is negatively regulated by the presence of antagonists [Miyazono et al., 2010]. Thus, we also explored the known antagonists for the BMP pathway, of which the expression
level was higher after differentiation stimulation. Gene transcript level of *Gremlin1* was increased after differentiation stimulation (Fig. 3A), but the extent of the increase in *Gremlin1* expression was relatively smaller (~2-fold). Therefore, characteristic changes in endogenous BMP activity can not be completely explained by the regulatory expression of *Gremlin1*. BMPs in FBS may also be responsible for induction of phosphorylated Smad1/5/8; BMP-2 is relatively heat-stable, and heat-inactivation of FBS for 30 min at 56°C would not decrease the bioactivity of BMP-2 [Ohta et al., 2005].

Gene transcript levels of *TGF-β2* and *TGF-β3* were increased after differentiation stimulation (Fig. 3B and C). Especially, expression level of *TGF-β2* on day 16 was ~5-fold higher than that on day -2, implying the role as an inducer of phosphorylation of Smad2 during the late phase of myogenesis. Myostatin, also known as GDF-8, is a strong inhibitor of myogenesis in skeletal muscle, and transmits its signal through type I receptor for activin (ALK4) or TGF-β (ALK5) and subsequently via Smad2 [Rebbapragada et al., 2003]; however, no significant expression of Myostatin was detected (Fig. 3D). In addition, Smad2 phosphorylation was detected in response to exogenously administered TGF-β1 but not activin A (Fig. 3E, lanes 1–3). Thus, Smad2 activity in C2C12 cells reflects endogenous TGF-β activity but not Myostatin and activin activities.

**PROPER BMP ACTIVITY BEFORE DIFFERENTIATION IS REQUIRED FOR DIFFERENTIATION OF C2C12 MYOBLASTS**

Dorsomorphin is an inhibitor of the BMP pathway, which inhibits the activation of BMP type I receptors, i.e., ALK2, 3 and 6, but not ALK4 and 5 in several types of cells [Yu et al., 2008b; Suenaga et al., 2010]. Treatment with dorsomorphin significantly down-regulated the expression of *Id1*, indicating the effectiveness of this compound.
also in C2C12 myoblasts (Fig. 4A). Immunofluorescent analyses revealed that treatment with dorsomorphin for 2 days before differentiation stimulation decreased myotube formation on day 8 (Fig. 4B). Dorsomorphin treatment in undifferentiated C2C12 cells also decreased the expression of MyHC after differentiation stimulation (Fig. 4C, upper), which was consistent with *MyHC IIb* mRNA on day 8 (Fig. 4D). In addition, the treatment resulted in a lower expression of Myf5, especially on day 0 (Fig. 4C, middle). Comparable results were also detected on gene transcript levels of *Myf5* and *MyoD* on day 0 (Fig. 4E).

Dorsomorphin was originally identified as an inhibitor for the AMPK pathway [Yu et al., 2008b]. Thus, results shown above may reflect effects of inhibition of endogenous AMPK activity. However, we could not detect phosphorylation of AMPKα1 at Ser485, a site of autophosphorylation [Hurley et al., 2006] (data not shown), suggesting that endogenous AMPK activity was lower. LDN-193189 is another inhibitor of BMP type I receptor, which is more selective and potent than dorsomorphin [Yu et al., 2008a]. Treatment with LDN-193189 for 2 days before differentiation stimulation caused down-regulation of *Id1*, *Myf5* and *MyoD* expression on day 0 (Fig. 5A-C), and *MyHC IIb* expression on day 8 (Fig. 5D). We further examined effects of pretreatment with noggin, a BMP antagonist [Yanagita, 2005], for 2 days before differentiation stimulation. Comparable results on expression of *Id1*, *Myf5*, *MyoD* and *MyHC IIb* were obtained (Fig. 5E-H). These results suggest that blocking BMP activity prior to differentiation stimulation impairs myotube formation, probably through down-regulation of MRF expression.

To test whether higher BMP activity in undifferentiated C2C12 cells enhances myogenic differentiation, BMP-2 was added to growth medium for 2 days before differentiation stimulation (Fig. 6); however, exogenous BMP-2 decreased myotube
formation on 8 days after differentiation stimulation in a dose-dependent manner (Fig. 6A). Expression of MyHC on day 8 was also decreased by BMP-2 addition both at the protein level (Fig. 6B) and at the mRNA level (Fig. 6C). Furthermore, treatment with BMP-2 down-regulated the expression of MyoD (Fig. 6B and D) and Myf5 (Fig. 6D). Experiments using the inhibitor and ligand suggest that the appropriate level of BMP activity in undifferentiated proliferating myoblasts is necessary for efficient differentiation into myotubes.

ENDOGENOUS TGF-β ACTIVITY AFTER DIFFERENTIATION INHIBITS EXCESS MYOTUBE FORMATION IN C2C12 CELLS

We next examined the role of endogenous TGF-β activity during the period after differentiation. A-83-01 is an inhibitor of ALK4 and ALK5 [Tojo et al., 2005]; as expected, the inhibitor blocked TGF-β1-induced Smad2 phosphorylation in C2C12 cells (Fig. 3E, lanes 2 and 6). A-83-01 also blocked TGF-β-induced Smad1/5/8 phosphorylation. Comparable results were also shown in a previous study [Wrighton et al., 2009]; pre-treatment with SB431542, another inhibitor of ALK5 [Inman et al., 2002], eliminated TGF-β-induced Smad1 phosphorylation in C2C12 cells. Treatment with A-83-01 from day 8 to 12 increased myotube formation (Fig. 7A), and the expression of MyHC (Fig. 7B). The treatment also increased the expression of Myf5 and MyoD (Fig. 7C). Culture under low-mitogen conditions does not differentiate all myoblasts into myotubes, and there are residual myoblasts after differentiation stimulation [Kitzmann et al., 1998; Menconi et al., 2008, Umemoto et al., unpublished data]. Mononucleated cells are classified into two types of cells on MyoD and Myf5; differentiated (MyoD-positive) and reserve (MyoD-negative) cells, which are undifferentiated but retain their myogenic potential [Yoshida et al., 1998]. Thus, these results suggest that the removal of endogenous TGF-β activity activates reserve cells, leading to differentiated myoblasts capable of differentiation into myotubes.
To examine whether inhibitory effect of endogenous TGF-β activity on myogenesis is limited to post-differentiation, A-83-01 was treated at various differentiation stages (Fig. 8A). Treatment with A-83-01 not only after differentiation (stages B-D) but also prior to differentiation (stage A) increased MyHC expression on day 12, although the effect of A-83-01 was stronger at stages C and D than at stages A and B (Fig. 8B and C). These results were consistent with gene transcript levels of MyHC IIb (Fig. 8D). Expression of Myf5 and MyoD was also higher in C2C12 cells treated with A-83-01 at stage D (Fig. 8E). Thus, endogenous TGF-β activity possibly inhibits myotube differentiation in a stage-independent manner.

**DISCUSSION**

Here we show differentiation-related changes in endogenous activities of the TGF-β family in C2C12 myoblasts. Endogenous BMP activity was higher in undifferentiated myoblasts, which was indispensable for myotube differentiation. Similar activity of BMP is shown during adipocyte differentiation; endogenous BMP activity in 3T3-L1 preadipocytes was higher before differentiation stimulation, and this activity is necessary for the preadipocytic property [Suenaga et al., 2010]. By contrast, TGF-β activity was relatively lower during the undifferentiated myoblast phase, and gradually increased after differentiation. Endogenous TGF-β activity negatively regulated myotube formation. The present results indicate that two representative TGF-β family members, i.e., TGF-β and BMP, endogenously control myogenesis in a stage-specific manner.

Previous studies revealed that the addition of BMP to low-mitogen differentiation medium inhibited myotube differentiation, and promoted osteoblast differentiation.
BMP-induced expression of Id1 is suggested to mediate the inhibition of myogenesis [Katagiri et al., 1994; Vinals and Ventura, 2004]. Id1 heterodimerizes with E proteins, which interferes with the formation of the active complex of E proteins and MyoD. Thus, the Id1 and E protein complex inhibits the function MyoD to function as a transcription factor [Benezra et al., 1990; Sun et al., 1991]. In addition, Id1 expression also accelerated the degradation of myogenin [Vinals and Ventura, 2004]. In the present study, myogenesis was also inhibited by the short-term addition of BMP-2 to growth medium but not to differentiation medium. MRFs are possibly modulated as described above, since exogenous BMP-2 induced Id1 expression in C2C12 undifferentiated myoblasts (Fig. 3A). The treatment also down-regulated the expression of Myf5 and MyoD (Fig. 4B and C). Since Myf5 and MyoD regulate the early events of myogenesis [Ludolph and Konieczny, 1995; Perry and Rudnick, 2000; Lluis et al., 2006], down-regulation of Myf5 and MyoD expression may be critical for the inhibition of myotube formation by exogenous BMP.

Decreased endogenous BMP activity by inhibitors for the BMP pathways before differentiation also inhibited myotube formation. Because the inhibitors potentiated the down-regulation of Myf5 and MyoD expression, the impaired action of MRFs in relation to the expression level may be responsible for suppressed myotube differentiation. It should be evaluated whether decreased endogenous BMP activity after differentiation inhibits myogenesis in future studies. Considering that Smads act as transcriptional regulators [Feng and Derynck, 2005; Massagué et al., 2005; Heldin, 2008], basal BMP activity may regulate expression of MRFs through Smad-dependent signaling. In contrast to the effects of exogenous BMP-2, the involvement of Id1 in the modulation of differentiation is unlikely, since the treatment with the inhibitors decreased the expression of Id1.
Optimal BMP activity before differentiation was therefore indispensable for myotube differentiation; both the increase and decrease in BMP activity resulted in impaired myotube formation. Molecular bases of the dual effects of BMP activity are currently unclear. Undifferentiated myoblasts possibly sense BMP concentrations and differentiate within the limited levels of BMP. The concentration-dependent effects of the TGF-β family have been well established; dpp, a Drosophila BMP molecule, acts as a morphogen during embryogenesis [Affolter and Basler, 2007]. Alternatively, a difference in the mode of changing BMP activity may affect the results; BMP activity was increased by adding BMP-2 to the culture medium, whereas it was decreased by treatment with the inhibitors for type I receptors for BMP, ALK2, 3 and 6 [Yu et al., 2008a, b; Suenaga et al., 2010]. As mentioned above, type II receptor acts as an activator of type I receptor in the current signaling model [Feng and Derynck, 2005; Massagué et al., 2005; Heldin, 2008]. However, BMP type II receptor has a long C-terminal tail with 530 amino acids after the kinase domain, where some effector molecules are bound to modulate the BMP signal through the non-Smad pathway in a type I receptor-independent manner [Miyazono et al., 2010].

Treatment with A-83-01 in C2C12 cells intrinsically enhanced myotube formation in a stage-independent manner, suggesting that endogenous TGF-β potentially inhibits myogenesis. This is basically consistent with the results by Maeda et al. [2004] using SB431542; SB431542 accelerated myotube formation of C2C12 cells, irrespective of serum concentration in culture medium. The enhanced myotube formation was especially evident by the treatment with A-83-01 in a late phase of myogenesis, which corresponded to the period of higher endogenous TGF-β activity. Consistent with the notion of the present results, exogenous TGF-β inhibited myotube formation in C2C12 cells under low-mitogen conditions [Olson et al., 1986]. However, TGF-β promoted
myoblast differentiation under high-mitogen conditions in L6E9 myoblasts [Zentella and Massagué, 1992], and stimulated the myogenic differentiation of uncommitted embryonic stem cells [Slager et al., 1993]. Culture conditions and cell differentiation stages possibly affect TGF-β effects. Furthermore, the expression of dominant-negative type II TGF-β receptor (TβRII), which lacks most of the cytoplasmic domain, including the kinase domain, delayed the differentiation of C2C12 myoblasts in low-mitogen differentiation medium [Filvaroff et al., 1994]. TβRII serine/threonine kinase also phosphorylated Par6, a regulator of cell polarity and tight-junction assembly, in a ligand-dependent manner [Ozdamar et al., 2005]. Thus, the kinase activity of TβRII beyond the phosphorylation of ALK5 may explain the discrepant results.

Other pathways including MAP kinase pathway, mTOR pathway and Hippo pathway regulate various stages of myoblast differentiation [Bennett and Tonks, 1997; Erbay and Chen, 2001; Park and Chen, 2005; Watt et al., 2010]. Since these pathways also affect TGF-β/BMP pathway [Feng and Derynck, 2005; Alarcón et al., 2009; Miyazono et al., 2010], fine-tuning of myogenesis can be achieved through the complex cross-talk between pathways.

ACKNOWLEDGEMENTS

This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, by The Science Research Promotion Fund from The Promotion and Mutual Aid Corporation for Private Schools of Japan, by grants for Graduate Schools from The Foundation for Japanese Private School Promotion, and by Core Stage Backup Grants from Kyoto University.
REFERENCES


Feng XH, Derynck R. 2005. Specificity and versatility in TGF-β signaling through


Norton JD. 2000. ID helix-loop-helix proteins in cell growth, differentiation and


Figure legends

Fig. 1. Time-course changes in Smad phosphorylation and Smad expression during myotube differentiation in C2C12 myoblasts
C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by culture in differentiation medium. (A) Equal amount of protein was subjected to Western blot analyses to detect expressions of phosphorylated and total Smad, and β-actin. A representative result is shown. (B and C) The band intensity of total and phosphorylated Smad2 and Smad8, and β-actin was quantified. The levels of phosphorylated Smad8 (B) and Smad2 (C) were plotted against days pre- or post-differentiation. Gene transcript levels of Smad1 (D), 5 (E) and 8 (F) or Smad2 (G) and 3 (H) were quantified by qRT-PCR. Smad expression was normalized to Hprt1 expression, and the expression on day -2 was set to 1. Data are shown as the mean ± SE (n = 3).

Fig. 2. Time-course changes in Ids expression during myotube differentiation in C2C12 myoblasts
C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by culture in differentiation medium. Gene transcript levels of Id1 (A), Id2 (B) and Id3 (C) were quantified by qRT-PCR. Expression of Ids was normalized to Hprt1 expression, and the expression on day -2 was set to 1. Data are shown as the mean ± SE (n = 3)

Fig. 3. Time-course changes in Gremlin1, TGF-β2, TGF-β3 and Myostatin expression during myotube differentiation in C2C12 myoblasts and Smad phosphorylation in response to TGF-β family ligand
C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by
culture in differentiation medium. Gene transcript levels of *Gremlin1* (A), *TGF-β2* (B) and *TGF-β3* (C) were quantified by qRT-PCR. Expression of the genes was normalized to *Hprt1* expression, and the expression on day -2 was set to 1. Data are shown as the mean ± SE (n = 3). (D) Time-course changes in *Myostatin* expression were examined by RT-PCR. A representative result is shown. (E) C2C12 cells were treated with or without A-83-01 (4 µM) for 15 min, followed by treatment with TGF-β1 (200 pM), activin A (4 nM) or BMP-2 (4 nM) for 1 h. Phosphorylated Smad1/5/8 and Smad2 were examined by Western blot analyses. A representative result is shown.

**Fig. 4. Myotube differentiation in C2C12 myoblasts treated with dorsomorphin before differentiation**

C2C12 myoblasts were cultured in growth medium with or without dorsomorphin (4 µM) or BMP-2 (4 nM) for 2 days prior to reaching confluence (day -2 to 0), followed by culture in differentiation medium. (A and E) Gene transcript levels of *Id1* (A), *Myf5* and *MyoD* (E) on day 0 were quantified by qRT-PCR in C2C12 myoblasts for 2 days before differentiation. The expression was normalized to *Hprt1* expression, and the expression in cells treated without the inhibitor or ligand was set to 1 (n = 2-3). (B) On day 8, myotube formation was examined by immunofluorescent analyses using anti-MyHC antibody. Fusion index was calculated as the ratio of nuclei incorporated into myotubes relative to total nuclei, and the index of cells treated without dorsomorphin was set to 1 (n = 3). (C) Time-course changes in expressions of MyHC, Myf5 and β-actin were examined during myotube differentiation in C2C12 myoblasts treated with or without dorsomorphin (4 µM) for 2 days prior to differentiation. (D) Gene transcript levels of *MyHC IIb* on day 8 were quantified by qRT-PCR in C2C12 myoblasts treated with or without dorsomorphin (4 µM) for 2 days before differentiation. The expression was normalized to *Hprt1* expression, and the expression
in cells treated without the inhibitor was set to 1 (n = 3).

Fig. 5. Response to treatment with LDN-193189 or noggin before differentiation in C2C12 cells
C2C12 myoblasts were cultured in growth medium with or without LDN-193189 (- and +: 0 and 100 nM, respectively) (A-D) or noggin (-, +, and ++: 0, 2.5, and 25 ng/ml, respectively) (E-H) for 2 days prior to reaching confluence (day -2 to 0), followed by culture in differentiation medium. Gene transcript levels of \(\text{Id1}\) (A and E), \(\text{Myf5}\) (B and F), and \(\text{MyoD}\) (C and G) on day 0, and \(\text{MyHC IIb}\) (D and H) on day 8 were quantified by qRT-PCR. The expression was normalized to \(\text{Hprt1}\) expression, and the expression in cells treated without the inhibitor was set to 1 (n = 3).

Fig. 6. Myotube differentiation in C2C12 myoblasts treated with BMP-2 before differentiation
(A) C2C12 myoblasts were cultured in growth medium with or without BMP-2 (-, +, and ++: 0, 0.8, and 4 nM, respectively) for 2 days prior to reaching confluence (day -2 to 0), followed by culture in differentiation medium. On day 8, myotube formation was examined by immunofluorescent analyses using anti-MyHC antibody. Fusion index was calculated as the ratio of nuclei incorporated into myotubes relative to total nuclei, and the index of cells treated without BMP-2 was set to 1 (n = 3). (B-D) Cells were treated with or without BMP-2 at 4 nM from day -2 to day 0, followed by culture in differentiation medium. (B) Time-course changes in expressions of MyHC, MyoD and \(\beta\)-actin were examined. (C and D) Gene transcript levels of \(\text{MyHC IIb}\) on day 8 (C) and \(\text{Myf5}\) and \(\text{MyoD}\) on day 0 (D) were quantified by qRT-PCR. The expression was normalized to \(\text{Hprt1}\) expression, and the expression in cells treated without BMP-2 was
set to 1 (n = 3).

Fig. 7. Myotube differentiation in C2C12 myoblasts treated with A-83-01 during differentiation

(A) C2C12 cells were cultured in differentiation medium with or without A-83-01 (4 µM) for 4 days (day 8 to 12). On day 12, myotube formation was examined by immunofluorescent analyses using anti-MyHC antibody. Fusion index was calculated as the ratio of nuclei incorporated into myotubes relative to total nuclei, and the index of cells treated without A-83-01 was set to 1 (n = 3). (B) Expression of MyHC and β-actin were examined in C2C12 cells treated with or without A-83-01 at the indicated concentration for 4 days (day 8–12). (C) Gene transcript levels of Myf5 and MyoD were quantified on day 12 by qRT-PCR in C2C12 cells treated with or without A-83-01 (4 µM) for 4 days (day 8–12). The expression was normalized to Hprt1 expression, and the expression in cells without treated with A-83-01 was set to 1 (n = 3).

Fig. 8. Effects of treatment with A-83-01 for various period on myotube differentiation

(A) C2C12 cells were cultured in growth medium (stage A) or differentiation medium (stages B-D) with or without A-83-01 (4 µM) for the indicated period. (B) On day 12, expression of MyHC and β-actin was examined by Western blot analyses. (C) The band intensity of MyHC and β-actin was quantified. The level of MyHC was normalized to that of β-actin, and the expression in cells without treated with A-83-01 at stage A was set to 100. (D and E) Gene transcript levels of MyHC IIb (D), and Myf5 and MyoD (E) were quantified on day 12 by qRT-PCR in C2C12 cells treated with or without A-83-01 (4 µM). The expression was normalized to Hprt1 expression, and the expression in cells without treated with A-83-01 at each stage was set to 1 (n = 3).
Figure 1 (Furutani)

**A**

<table>
<thead>
<tr>
<th>day:</th>
<th>-2</th>
<th>0</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>16</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSmad1/5/8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smad1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smad8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pSmad2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smad2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B**

arbitrary unit

- - pSmad8
- - total Smad8
- - pSmad8/total Smad8
- - pSmad8/β-actin

**C**

arbitrary unit

- - pSmad2
- - total Smad2
- - pSmad2/total Smad2
- - pSmad2/β-actin

**D**

**E**

**F**

**G**

**H**

relative mRNA level

- - Smad1
- - Smad5
- - Smad8
- - Smad2
- - Smad3

relative mRNA level

- - day
- - day
- - day
- - day
- - day
Figure 2 (Furutani)

A. $Id1$

B. $Id2$

C. $Id3$

Relative mRNA level vs. day
**Figure 3 (Furutani)**

(A) **Gremlin1**

(B) **TGF-β2**

(C) **TGF-β3**

(D) Western blot analysis showing **Myostatin** and **Gapdh** expression over days -2, 0, 2, 4, 8, 12, and 16.

(E) Inhibitor: control (−), A-83-01. Ligands: TGF-β1, Activin A, BMP-2. Western blotting for **pSmad1/5/8**, **Smad1**, **pSmad2**, and **Smad2** expression.
A  

B  

C  

D  

E  

Figure 4 (Furutani)
Figure 5 (Furutani)

Relative mRNA level of Id1, Myf5, MyoD, and MyHC IIb under different treatments with Noggin and dorsomorphin, with or without LDN-193189.

A: Id1
B: Myf5
C: MyoD
D: MyHC IIb

A - B: - + + +
C - D: - + + +
E - F: - + + +
G - H: - + + +

Treatments: Noggin, dorsomorphin, and LDN-193189.
Figure 6 (Furutani)

(A) BMP-2

(B) BMP-2:

<table>
<thead>
<tr>
<th>day:</th>
<th>-</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>MyHC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MyoD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

(C) MyHC IIb

(D) Myf5, MyoD

relative mRNA level

relative fusion index

BMP-2: - + ++

relative mRNA level

BMP-2: - + ++
Figure 7 (Furutani)

A

A-83-01

-  +

B

A-83-01 (µM): 0 2 4

MyHC

β-actin

1 2 3

C

Myf5

MyoD

relative mRNA level

relative mRNA level
Figure 8 (Furutani)

A. Diagram showing differentiation stimulation over days -2, 0, 4, 8, and 12.

B. Chart indicating stages A, B, C, and D with different treatments:

- A-83-01:
  - Stage A: -
  - Stage B: +
  - Stage C: -
  - Stage D: +
  - MyHC and β-actin levels at stages 1 to 8.

C. Bar graph showing arbitrary units for stages A, B, C, and D with vehicle and A-83-01 treatments.

D. Bar graph showing relative mRNA levels for MyHC IIb with vehicle and A-83-01 treatments.

E. Bar graphs showing relative mRNA levels for Myf5 and MyoD with vehicle and A-83-01 treatments.